GSK Pharma Managing Director Bhushan Akshikar shared the company’s transformation with TOI. “We remain rooted in our purpose to bring innovation at scale, and with impact,” he told TOI, adding that the company’s portfolio has been revamped to align with its global focus as a biopharma company. GSK’s growth in India is now driven by innovation, with new therapies boosting sales.
As part of its strategy to strengthen its preventive healthcare portfolio, GSK Pharma plans to launch more adult vaccines. This move signals a shift from the traditional focus on infant immunization to a broader preventive approach targeting people of all ages. GSK aims to build a comprehensive healthcare ecosystem to support this initiative.
On the pricing front, Akshikar pointed out that GSK Pharma has always maintained a tiered pricing strategy in India. He explained that while some of their products, such as paracetamol, fall under the National List of Essential Medicines (NLEM) and are subject to price control, the company manages to offer competitive pricing without compromising quality. “We’ve always had tiered pricing in India,” he said, citing the example of their popular paracetamol brand Calpol, which operates within the same price range as commoditized products.
GSK Pharma’s strategic focus on specialty treatments and preventive healthcare reflects its commitment to innovation as it enters its second century in India. The company’s efforts to expand its vaccine offerings and introduce cutting-edge cancer therapies signal a continued dedication to addressing India’s evolving healthcare needs.
